Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million
09. November 2017 16:05 ET
|
Sonoma Pharmaceuticals, Inc.
Product revenue up 15%, compared to the June 2017 quarterPrescriptions filled were up 42% over last year and up 14% over the June 2017 quarter to 19,660EBITDA loss reduced to $2.3 millionCash on hand...
Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products
31. Oktober 2017 07:45 ET
|
Sonoma Pharmaceuticals, Inc.
Brazilian Ministério da Saúde Approves Marketing of Sonoma Pharmaceuticals’ Products: Lasercyn™, Gramaderm®, Epicyn™ and Pediacyn™ Brazilian Dermatology Market Second Largest in the World Behind the...
Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call
26. Oktober 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that financial results for its fiscal second quarter 2018, ended...
Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis
03. Oktober 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
Sonoma Pharmaceuticals Announces Commercialization of MicrocynAH® Animal Healthcare Products in Japan
14. September 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...
Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018
08. August 2017 16:05 ET
|
Sonoma Pharmaceuticals, Inc.
Product revenue for first quarter up 49%, compared to the same period last year, driven by growth in U.S. dermatology salesConference Call Begins at 4:30pm EDT Today PETALUMA, Calif., Aug. 08, 2017 ...
Sonoma Pharmaceuticals Announces Fiscal First Quarter 2018 Financial Results and Conference Call
25. Juli 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal first quarter 2018, ended...
CORRECTING and REPLACING -- Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
13. Juli 2017 09:57 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sonoma Pharmaceuticals, Inc., please note that in the first paragraph of the release...
Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data
13. Juli 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
Quarter ended June 30, 2017: Highest quarterly number of prescriptions filled 24% up over prior March quarter 201746% up over June quarter 2016 PETALUMA, Calif., July 13, 2017 (GLOBE NEWSWIRE) --...
Sonoma Pharmaceuticals Announces Publication of Consensus Report Describing Celacyn's (Hypochlorous Acid) Impact on Post-Procedure Treatment and Scar Prevention
28. Juni 2017 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- A distinguished panel of U.S. dermatologists and plastic surgeons explored current literature to establish the value of hypochlorous acid (HOCl)...